Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Research
Molecular Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Tumor Microenvironment and Immunobiology

IL8 Expression Is Associated with Prostate Cancer Aggressiveness and Androgen Receptor Loss in Primary and Metastatic Prostate Cancer

Janielle P. Maynard, Onur Ertunc, Ibrahim Kulac, Javier A. Baena-Del Valle, Angelo M. De Marzo and Karen S. Sfanos
Janielle P. Maynard
1Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Janielle P. Maynard
Onur Ertunc
1Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Onur Ertunc
Ibrahim Kulac
1Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ibrahim Kulac
Javier A. Baena-Del Valle
1Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angelo M. De Marzo
1Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
2Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
3Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Angelo M. De Marzo
Karen S. Sfanos
1Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
2Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
3Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ksandel1@jhmi.edu
DOI: 10.1158/1541-7786.MCR-19-0595 Published January 2020
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    RISH analysis revealed differential mRNA expression of IL1β, IL6, IL8, and IL10 in prostatectomy tissues. Modest IL1β expression was observed primarily in stromal compartment cells consistent with immune/inflammatory cells (arrows), or at times in atrophic epithelial cells (arrowhead). IL6 expression was largely confined to the stromal compartment in endothelial cell lining vessels (arrowheads) and on immune cells (arrows). IL8 was the most highly expressed cytokine assessed, observed both in benign and tumor regions. IL8 expression was predominant in atrophic glands (red arrowheads) but was also seen on immune cells (red arrows) and potentially tumor cells (blue arrowhead). Limited IL10 expression was observed on immune cells (arrows). Cytokine expression was dramatically increased in highly inflamed regions.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    RISH analysis demonstrated IL8 mRNA expression in prostate tissues from men with prostate cancer. IL8 expression was predominant in atrophic glands particularly (A) in regions of intense inflammation, (B) atrophic glands involving basal cell proliferation, and (C) atrophic glands encapsulating corpora amylacea. IL8 expression was markedly increased in (D) urethral tissue in most cases. There was considerable IL8 expression observed in (E and F) tumor regions on immune infiltrates and in tumor cells (arrowheads). G and H, Concurrent IL8 RISH (brown) and CK8 IHC (red) analysis confirms that IL8 mRNA is expressed within prostate epithelial cells (arrows) in tumor regions; (I) CD68 (red)-positive macrophages do not express IL8, but some (J) CD66 (red)-positive neutrophils do (black arrows). There were also some IL8− neutrophils (red arrow).

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Quantification of RISH IL8 expression in TMAs showed (A) significantly increased expression in tumor regions compared with benign regions. B, There was elevated IL8 expression in both benign and tumor regions in higher-grade cases. C, There was no apparent difference in expression between races, (D) but a modest increase was observed in higher-grade tumors compared with lower-grade tumors from AA and EA men, but only significant for EA men. E, There was significantly elevated IL8 expression in atrophic glands compared with the remaining regions of the prostate. F, IHC analysis of CD66 showed comparable neutrophils in benign and tumor regions. Each data point represents the median of up to 4 TMA spots except for E where all TMA spots are shown. Center line shows the median for each group (*, P < 0.05; **, P < 0.005; ***, P < 0.0005; and ****, P < 0.0001).

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    RISH analysis of a TMA set constructed from metastatic tumors obtained via autopsy showed that (A) IL8 mRNA is differentially expressed in every site assessed. B, Metastatic tissues from liver had the most intense signal compared with prostate (P < 0.0001). Each data point represents a TMA spot, and centerline shows the median for each group. The number of patients from which each site was sampled is noted (n = x). C, IL8 RISH analysis revealed IL8 mRNA expression in AR-null cell lines compared with AR-expressing cell lines (**, P < 0.005 and ****, P < 0.0001).

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    A, AR-null metastatic tissues have modestly elevated IL8 mRNA in epithelial cells compared with in AR-positive metastases (IL8 CISH left, AR IHC right). B, Regions of prostatic atrophy with dramatically elevated IL8 expression (red arrowheads) were more likely to have AR downregulation in radical prostatectomy tissues.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    IL8 RISH analysis of 42 LuCaP PDX TMA set revealed (A and C) comparable IL8 mRNA expression between PDX and castration-resistant PDX lines, but (B and C) elevated IL8 expression in AR− PDX compared with AR+ PDX lines. Each data point in A and B represents the mean of 3 TMA spots, and the centerline shows the mean of each group. ***, P < 0.0001.

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    A, ChIP-seq analysis shows AR binding at the IL8 promoter (blue arrow) in LNCaP and C4-2b cell lines. B, LPS treatment induced IL8 protein expression in AR-negative PC3 cells but not in AR-positive LNCaP, LAPC4, or CWR22rv1 cells, even with AR antagonist (enzalutamide) treatment. C, AR-targeted shRNA (AR3717, AR3718, and AR26211) knockdown in LNCaP cells resulted in modest IL8 mRNA expression.

Additional Files

  • Figures
  • Supplementary Data

    • Supplementary Figure S1 - Supplementary Figure S1 shows positive and negative controls for IL-1B, IL-6, IL-8, and IL-10 RISH and a comparison of IL-8 IHC versus IL-8 RISH.
    • Supplementary Figure S2 - Supplementary Figure S2 shows quantification of IL-8 expression by RISH in whole tissue sections and TMAs by tumor grade and race.
    • Supplementary Figure S3 - Supplementary Figure S3 shows quantification of CD66+ neutrophils in TMAs.
    • Supplementary Figure S4 - Supplementary Figure S4 shows examples of liver metastases stained for IL-8 by RISH and CD66 by IHC as well as quantification of IL-8 and AR in metastatic tissues of AA versus EA men.
    • Supplementary Figure S5 - Supplementary Figure S5 shows CCLE data on IL-8 and AR mRNA co-expression as well as examples of IL-8 expression in AR null metastases.
    • Supplementary Figure S6 - Supplementary Figure S6 shows cBioPortal data for IL-8 and AR expression in primary prostate cancer, metastatic, and neuroendocrine tumors as well as CXCR1, CXCR2, and AR co-expression.
    • Supplementary Figure S7 - Supplementary Figure S7 shows IL-8 western blot and RISH on LPS treated PC3 and DU145 cells and LNCaP cells with or without enzalutamide treatment.
    • Supplementary Table S1 - Patient characteristics for whole tissue sections, 120 case TMA set, and autopsy TMA set.
PreviousNext
Back to top
Molecular Cancer Research: 18 (1)
January 2020
Volume 18, Issue 1
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
IL8 Expression Is Associated with Prostate Cancer Aggressiveness and Androgen Receptor Loss in Primary and Metastatic Prostate Cancer
(Your Name) has forwarded a page to you from Molecular Cancer Research
(Your Name) thought you would be interested in this article in Molecular Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
IL8 Expression Is Associated with Prostate Cancer Aggressiveness and Androgen Receptor Loss in Primary and Metastatic Prostate Cancer
Janielle P. Maynard, Onur Ertunc, Ibrahim Kulac, Javier A. Baena-Del Valle, Angelo M. De Marzo and Karen S. Sfanos
Mol Cancer Res January 1 2020 (18) (1) 153-165; DOI: 10.1158/1541-7786.MCR-19-0595

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
IL8 Expression Is Associated with Prostate Cancer Aggressiveness and Androgen Receptor Loss in Primary and Metastatic Prostate Cancer
Janielle P. Maynard, Onur Ertunc, Ibrahim Kulac, Javier A. Baena-Del Valle, Angelo M. De Marzo and Karen S. Sfanos
Mol Cancer Res January 1 2020 (18) (1) 153-165; DOI: 10.1158/1541-7786.MCR-19-0595
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Dietary Fatty Acids Inhibit Prostate Cancer Progression
  • Neoantigen Pipeline Predicts Response to ICB
  • HS in Glioblastoma EGFR Inhibitor Resistance
Show more Tumor Microenvironment and Immunobiology
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Rapid Impact Archive
  • Meeting Abstracts

Information for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCR

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Research
eISSN: 1557-3125
ISSN: 1541-7786

Advertisement